RAC — Rithm Acquisition Corp.

Summary of Rite Aid Corporation Q1 2024 Earnings Call

1. Key Financial Results and Metrics

• Adjusted EBITDA: $91.7 million, down from $100.1 million year-over-year.
• Net Loss: $306.7 million ($5.56 per share), with an adjusted net loss of $40.1 million ($0.73 per share). The loss includes a $152 million impairment charge for goodwill at Elixir.
• Revenues: Increased by 3.4% year-over-year, primarily driven by pharmacy sales, which grew 13.3%, offset by a decline in front-end sales (down 4.4%).
• Script Growth: Same-store prescriptions increased by 4.7% (7.4% excluding COVID impacts).
• Cash Flow: Operating cash use of $372.5 million, with liquidity at approximately $1.15 billion.

2. Strategic Updates and Business Highlights

• Pharmacy Initiatives: Strong script growth driven by adherence initiatives and improved recovery rates. A pilot program to reduce abandoned scripts is being rolled out across all stores.
• Elixir Insurance: The company plans to exit the individual Medicare Part D market due to unfavorable shifts in member composition and increased medical loss ratios. Elixir will continue to operate in the group Medicare market.
• Front-End Sales Strategy: Addressing challenges with perishables and shrink through vendor transitions and new leadership in loss prevention. The launch of new owned brands is also a focus.
• Cost Control: Retail SG&A improved by approximately $5 million due to cost control initiatives and store closures.

3. Forward Guidance and Outlook

• Adjusted EBITDA Guidance: Expected to be between $90 million and $100 million for Elixir and $240 million to $260 million for retail.
• Total Revenue Guidance: Revised to between $22.6 billion and $23 billion, reflecting increased sales of high-dollar GLP-1s and Elixir utilization, offset by lower front-end sales.
• Capital Expenditures: Expected to be reduced to $175 million, with a forecasted cash use of $100 million to $150 million in fiscal 2024.

4. Bad News, Challenges, or Points of Concern

• Higher Medical Loss Ratio: Elixir is facing a higher-than-expected medical loss ratio due to adverse selection during enrollment, impacting profitability.
• Front-End Sales Decline: Front-end sales were negatively impacted by a 3.8% decline in transactions, driven by reduced demand for respiratory products and inventory challenges.
• Shrink Issues: Increased shrink costs, which were about $9 million higher than the previous year, continue to be a significant concern.
• Competitive Pressures: Ongoing challenges in the retail pharmacy market, including competition and changing consumer behaviors, may affect future performance.

5. Notable Q&A Insights

• COVID Impact: COVID vaccine administration dropped significantly from 1.7 million last year to less than 500,000 this quarter, impacting revenues.
• Kroger Dispute: While the impact of the Kroger dispute on scripts has not been quantified, Rite Aid is capturing a fair share of volume.
• Vendor Transition: The transition of perishable food vendors is complete, but early signs indicate continued pressure on front-end sales.
• Debt Management: The company is evaluating options for addressing 2025 debt maturities but did not provide specific details on the discussions.
• Elixir Membership Losses: The exit from the individual Part D market will eliminate approximately 300,000 lives, which are currently breakeven in profitability.

This summary encapsulates the key points from Rite Aid's Q1 2024 earnings call, highlighting both the financial metrics and strategic initiatives, while also addressing the challenges and outlook for the company.